All News

Article

Day 1 Top 5 - EULAR2020

Jack Cush, MD Jun 08, 2020

Here is my top-five from day one at EULAR:

#EULAR2020 #op0054 DISCOVER 1&2 rct results for Guselkumab in PsA w/ sacroiliitis: significantly better BaSDAI, improved spinal pain& ASDAS-CRP vs PBO suggestive of good clincial efficacy. No radiographic data @RheumNow https://t.co/MeXV08hcBU

#EULAR2020 #op0051 presence of Structural Enthrseal Lesions (SEL) in PSO associated w/higher risk of progression to PsA: 37.5%If SEL present vs 3.4% no SEL/no arthalgia& 15.2% no SEL/+arthralgia. Highest risk in PSO w/SEL+arthralgia at 42.8% @RheumNow https://t.co/7knYXeap7l

How do you approach your PsA patients with suboptimal response to MTX in moderate doses?

#EULAR2020 #op0050 RCT ph4 results: in inadequately controlled PsA addition of ADA results in better outcomes in terms MDA, ACR20, PASI75, HAQ-DI&LEI as opposed to MTX dose escalation @RheumNow https://t.co/iMgCkRawCl

How does virtual EULAR make you feel? @RheumNow

Not missing being torn between ballroom 1 and exhibit hall 2 😃 #EULAR2020 #onlinelearning #VirtualConference @RheumNow https://t.co/rHLquYPjW5

#EULAR2020 #LB0001 SELECT-PsA-1 Upadacitinib vs PBO vs ADA: UPA 15/30 mg non-inferior &UPA 30 superior to ADA for ACR20. At wk12 ACR 20 70.6% UPA15, 78.5% UPA30 vs 36.2%PBO & 65%ADA. Better ACR50/70 &MDA va PBO. No new safety signals. @RheumNow https://t.co/QZkMdoqXEC

#EULAR2020 #op0015 relationship btw sUA &mortality in the US: increased mortality in M w/ low sUA but not F. could be attributed to uricosuric effect of uncontrolled hyperglycemia ( high incidence of DM)? Lower Alzheimer’s mortality in M&F w/high sUA. @RheumNow https://t.co/E4HVXASKYy

#EULAR2020 #op0079 ASAS-MRI group offers updated definition of the structural lesions in SI joints in AxSpA: -erosion in >=2 consecutive slices or in >=3 SIJ quadrants - fat lesions w/depth >1cm in >=1SIJ quadrant are high priority candidates @RheumNow https://t.co/EU1WWqJ4h3

#eular2020 #op0205 phase 1 trial of novel URAT1 inhibitor D-0120 in healthy adults: safe up to 20 mg/d after 7 days. Significant reduction of sUA peaks at 4-8h & lasts up to 24h @RheumNow

#EULAR2020 #op0106 Cosentyx 150mg demonstrates clinical improvement in NrAxSpA Sx in Ph3 PREVENT 52wk study. Significant improvement in ASAS40, BASDAI50& ASdAS-CRP ID. MRI BME score significantly decreased (-1.68&-1.03 (no LD) vs -0.39 PBO) @RheumNow https://t.co/UX7mkJ8qMJ

#EULAR2020 #op0169 US claims database analysis reveals that gout and DM make for a dangerous combination: significantly higher risk of amputations in pts with gout+DM at 0.77% as oppose to DM w/out gout 0.461% & gout w/out DM 0.162% @RheumNow

#EULAR2020 #op0201 nationwide cohort study: higher incidence of dementia in SLE (3.9/1000pys) vs non-SLE ( 2.73/1000pys). HR 1.43. In SLE risk of Alzheimer’s 1.4x &risk of vascular dementia 1.6x Higher than non-SLE cohort. Further studies to identify mechanism needed @RheumNow

#EULAR2020 #op0192 UK Biobank and IMPALA studies: metabolic body composition of PsA pts w/increased VAT,ectopic liver fat distribution & ⬆️ abdominal fat index associated w/increased risk of CHD&T2DM @RheumNow https://t.co/CwwAB2yUid

How often do you use MRI of peripheral joints for diagnosis or monitoring of PsA?

#EULAR2020 #op0182 delayed gadolinium-enhanced MRI study reveals proteoglycan loss in articulate cartilage in PsA associated w/severity of periarticular inflammation, synovitis &flexor tenosynovits but not bone erosion or prolypheration. @RheumNow https://t.co/ZJBDnZuYbB

#EULAR2020 #op0202-hpr 🇬🇧 study remind that resistant training benefits patients with inflammatory arthritides: improved function, wellbeing, self-efficacy, strength and fatigue.improved balance&endurance helps prevent falls @RheumNow https://t.co/MH7VD6zH9t

#EULAR2020 #op0143 a nationwide study concludes GCA pts at higher risk for sarcoma (HR 2.14), kidney cancer (1.6), hematological malignancies (HL2.42&non-HL1.66). Overall cancer HR 1.29. Time to diagnosis shorter in GCA (~48mo) vs controls (~58mo) @RheumNow https://t.co/obAlZw2gei

#EULAR2020 #op0148 real world European study of Mepolizumab in 142 pts w/EGPA shows significant improvement of general, ENT, pulm&neuro symptoms. Significant reduction in BVAS, 90%decrease of asthma attacks by 12 mo, decreased steroid use. 21.1%non-serious AEs @RheumNow https://t.co/fN4tKPvUaE

Topics

All News

Day 1 Top 5 - EULAR2020

Do you get our email newsletter?